Pfizer Inc (NYSE:PFE) — Market Cap & Net Worth
Market Cap & Net Worth: Pfizer Inc (PFE)
Pfizer Inc (NYSE:PFE) has a market capitalization of $149.70 Billion ($149.70 Billion) as of May 2, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #151 globally and #86 in its home market, demonstrating a -1.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pfizer Inc's stock price $26.33 by its total outstanding shares 5685707552 (5.69 Billion). Analyse how efficiently does Pfizer Inc generate cash to see how efficiently the company converts income to cash.
Pfizer Inc Market Cap History: 2015 to 2026
Pfizer Inc's market capitalization history from 2015 to 2026. Data shows growth from $121.10 Billion to $149.70 Billion (1.47% CAGR).
Index Memberships
Pfizer Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Composite Average
DJA
|
$16.47 Trillion | 0.91% | #27 of 65 |
|
ARCA Pharmaceutical
DRG
|
$3.19 Trillion | 4.70% | #7 of 24 |
|
S&P 500 Index
GSPC
|
$59.46 Trillion | 0.27% | #75 of 503 |
|
S&P 100
OEX
|
$42.94 Trillion | 0.39% | #65 of 101 |
Weight: Pfizer Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pfizer Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pfizer Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.26x
Pfizer Inc's market cap is 2.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.22x
Pfizer Inc's market cap is 18.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $126.47 Billion | $52.82 Billion | $7.21 Billion | 2.39x | 17.53x |
| 2017 | $146.59 Billion | $52.55 Billion | $21.30 Billion | 2.79x | 6.88x |
| 2018 | $182.98 Billion | $53.65 Billion | $11.15 Billion | 3.41x | 16.41x |
| 2019 | $170.35 Billion | $41.17 Billion | $16.27 Billion | 4.14x | 10.47x |
| 2020 | $175.86 Billion | $41.65 Billion | $9.16 Billion | 4.22x | 19.20x |
| 2021 | $293.15 Billion | $81.29 Billion | $22.15 Billion | 3.61x | 13.24x |
| 2022 | $262.64 Billion | $100.33 Billion | $31.36 Billion | 2.62x | 8.37x |
| 2023 | $154.26 Billion | $59.55 Billion | $2.13 Billion | 2.59x | 72.32x |
| 2024 | $150.84 Billion | $63.63 Billion | $8.02 Billion | 2.37x | 18.81x |
| 2025 | $141.57 Billion | $62.58 Billion | $7.77 Billion | 2.26x | 18.22x |
Competitor Companies of PFE by Market Capitalization
Companies near Pfizer Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Pfizer Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $862.20 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #23 globally with a market cap of $547.37 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #37 globally with a market cap of $365.30 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $862.20 Billion | $963.33 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #23 | Johnson & Johnson | NYSE:JNJ | $547.37 Billion | $227.19 |
| #37 | AbbVie Inc | NYSE:ABBV | $365.30 Billion | $206.60 |
Pfizer Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Pfizer Inc's market cap moved from $121.10 Billion to $ 149.70 Billion, with a yearly change of 1.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $149.70 Billion | +5.74% |
| 2025 | $141.57 Billion | -6.14% |
| 2024 | $150.84 Billion | -2.22% |
| 2023 | $154.26 Billion | -41.26% |
| 2022 | $262.64 Billion | -10.41% |
| 2021 | $293.15 Billion | +66.70% |
| 2020 | $175.86 Billion | +3.24% |
| 2019 | $170.35 Billion | -6.90% |
| 2018 | $182.98 Billion | +24.83% |
| 2017 | $146.59 Billion | +15.91% |
| 2016 | $126.47 Billion | +4.43% |
| 2015 | $121.10 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Pfizer Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $149.70 Billion USD |
| MoneyControl | $149.70 Billion USD |
| MarketWatch | $149.70 Billion USD |
| marketcap.company | $149.70 Billion USD |
| Reuters | $149.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more